Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Multiple Sclerosis (MS) Drugs market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Multiple Sclerosis (MS) Drugs market segmented into
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Based on the end-use, the global Multiple Sclerosis (MS) Drugs market classified into
RRMS
SPMS
PPMS
PRMS
Based on geography, the global Multiple Sclerosis (MS) Drugs market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL MULTIPLE SCLEROSIS (MS) DRUGS INDUSTRY
2.1 Summary about Multiple Sclerosis (MS) Drugs Industry
2.2 Multiple Sclerosis (MS) Drugs Market Trends
2.2.1 Multiple Sclerosis (MS) Drugs Production & Consumption Trends
2.2.2 Multiple Sclerosis (MS) Drugs Demand Structure Trends
2.3 Multiple Sclerosis (MS) Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
4.2.2 Novantrone (Mitoxantrone)
4.2.3 Gilenya (Fingolimod, Fty720)
4.2.4 Aubagio (Teriflunomide)
4.2.5 Tecfidera (Dimethyl Fumarate)
4.2.6 Firategrast (Sb683699, T-0047)
4.2.7 Siponimod (Baf312)
4.2.8 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 RRMS
4.3.2 SPMS
4.3.3 PPMS
4.3.4 PRMS
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
5.2.2 Novantrone (Mitoxantrone)
5.2.3 Gilenya (Fingolimod, Fty720)
5.2.4 Aubagio (Teriflunomide)
5.2.5 Tecfidera (Dimethyl Fumarate)
5.2.6 Firategrast (Sb683699, T-0047)
5.2.7 Siponimod (Baf312)
5.2.8 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 RRMS
5.3.2 SPMS
5.3.3 PPMS
5.3.4 PRMS
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
6.2.2 Novantrone (Mitoxantrone)
6.2.3 Gilenya (Fingolimod, Fty720)
6.2.4 Aubagio (Teriflunomide)
6.2.5 Tecfidera (Dimethyl Fumarate)
6.2.6 Firategrast (Sb683699, T-0047)
6.2.7 Siponimod (Baf312)
6.2.8 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 RRMS
6.3.2 SPMS
6.3.3 PPMS
6.3.4 PRMS
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
7.2.2 Novantrone (Mitoxantrone)
7.2.3 Gilenya (Fingolimod, Fty720)
7.2.4 Aubagio (Teriflunomide)
7.2.5 Tecfidera (Dimethyl Fumarate)
7.2.6 Firategrast (Sb683699, T-0047)
7.2.7 Siponimod (Baf312)
7.2.8 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 RRMS
7.3.2 SPMS
7.3.3 PPMS
7.3.4 PRMS
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
8.2.2 Novantrone (Mitoxantrone)
8.2.3 Gilenya (Fingolimod, Fty720)
8.2.4 Aubagio (Teriflunomide)
8.2.5 Tecfidera (Dimethyl Fumarate)
8.2.6 Firategrast (Sb683699, T-0047)
8.2.7 Siponimod (Baf312)
8.2.8 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 RRMS
8.3.2 SPMS
8.3.3 PPMS
8.3.4 PRMS
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
9.2.2 Novantrone (Mitoxantrone)
9.2.3 Gilenya (Fingolimod, Fty720)
9.2.4 Aubagio (Teriflunomide)
9.2.5 Tecfidera (Dimethyl Fumarate)
9.2.6 Firategrast (Sb683699, T-0047)
9.2.7 Siponimod (Baf312)
9.2.8 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 RRMS
9.3.2 SPMS
9.3.3 PPMS
9.3.4 PRMS
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Bayer AG
10.1.2 Bayhill Therapeutics
10.1.3 Biogen Idec
10.1.4 Cinnagen
10.1.5 Daiichi Sankyo
10.1.6 Eli Lilly
10.1.7 Fast Forward Llc
10.1.8 Antisense Therapeutics
10.1.9 Apitope
10.1.10 Five Prime Therapeutics
10.1.11 Genmab
10.1.12 Artielle Immunotherapeutics
10.1.13 Genzyme
10.1.14 Glaxosmithkline
10.1.15 Gw Pharmaceuticals
10.1.16 Innate Immunotherapeutics
10.2 Multiple Sclerosis (MS) Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Bayer AG
10.2.2 Bayhill Therapeutics
10.2.3 Biogen Idec
10.2.4 Cinnagen
10.2.5 Daiichi Sankyo
10.2.6 Eli Lilly
10.2.7 Fast Forward Llc
10.2.8 Antisense Therapeutics
10.2.9 Apitope
10.2.10 Five Prime Therapeutics
10.2.11 Genmab
10.2.12 Artielle Immunotherapeutics
10.2.13 Genzyme
10.2.14 Glaxosmithkline
10.2.15 Gw Pharmaceuticals
10.2.16 Innate Immunotherapeutics
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
List of Table
1.Table Multiple Sclerosis (MS) Drugs Product Type Overview
2.Table Multiple Sclerosis (MS) Drugs Product Type Market Share List
3.Table Multiple Sclerosis (MS) Drugs Product Type of Major Players
4.Table Brief Introduction of Bayer AG
5.Table Brief Introduction of Bayhill Therapeutics
6.Table Brief Introduction of Biogen Idec
7.Table Brief Introduction of Cinnagen
8.Table Brief Introduction of Daiichi Sankyo
9.Table Brief Introduction of Eli Lilly
10.Table Brief Introduction of Fast Forward Llc
11.Table Brief Introduction of Antisense Therapeutics
12.Table Brief Introduction of Apitope
13.Table Brief Introduction of Five Prime Therapeutics
14.Table Brief Introduction of Genmab
15.Table Brief Introduction of Artielle Immunotherapeutics
16.Table Brief Introduction of Genzyme
17.Table Brief Introduction of Glaxosmithkline
18.Table Brief Introduction of Gw Pharmaceuticals
19.Table Brief Introduction of Innate Immunotherapeutics
20.Table Products & Services of Bayer AG
21.Table Products & Services of Bayhill Therapeutics
22.Table Products & Services of Biogen Idec
23.Table Products & Services of Cinnagen
24.Table Products & Services of Daiichi Sankyo
25.Table Products & Services of Eli Lilly
26.Table Products & Services of Fast Forward Llc
27.Table Products & Services of Antisense Therapeutics
28.Table Products & Services of Apitope
29.Table Products & Services of Five Prime Therapeutics
30.Table Products & Services of Genmab
31.Table Products & Services of Artielle Immunotherapeutics
32.Table Products & Services of Genzyme
33.Table Products & Services of Glaxosmithkline
34.Table Products & Services of Gw Pharmaceuticals
35.Table Products & Services of Innate Immunotherapeutics
36.Table Market Distribution of Major Players
37.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
38.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
39.Table Global Multiple Sclerosis (MS) Drugs Market Forecast (Million USD) by Region 2021f-2026f
40.Table Global Multiple Sclerosis (MS) Drugs Market Forecast (Million USD) Share by Region 2021f-2026f
41.Table Global Multiple Sclerosis (MS) Drugs Market Forecast (Million USD) by Demand 2021f-2026f
42.Table Global Multiple Sclerosis (MS) Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f
List of Figure
1.Figure Global Multiple Sclerosis (MS) Drugs Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2.Figure Global Multiple Sclerosis (MS) Drugs Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3.Figure Global Multiple Sclerosis (MS) Drugs Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4.Figure Global Multiple Sclerosis (MS) Drugs Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5.Figure Global Multiple Sclerosis (MS) Drugs Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6.Figure Global Multiple Sclerosis (MS) Drugs Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7.Figure Global Multiple Sclerosis (MS) Drugs Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8.Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9.Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12.Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13.Figure Copaxone (Glatiramer Acetate, Copolymer 1) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14.Figure Novantrone (Mitoxantrone) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15.Figure Gilenya (Fingolimod, Fty720) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16.Figure Aubagio (Teriflunomide) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17.Figure Tecfidera (Dimethyl Fumarate) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18.Figure Firategrast (Sb683699, T-0047) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
19.Figure Siponimod (Baf312) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21.Figure RRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22.Figure SPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23.Figure PPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24.Figure PRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26.Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27.Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28.Figure Copaxone (Glatiramer Acetate, Copolymer 1) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29.Figure Novantrone (Mitoxantrone) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30.Figure Gilenya (Fingolimod, Fty720) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31.Figure Aubagio (Teriflunomide) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32.Figure Tecfidera (Dimethyl Fumarate) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33.Figure Firategrast (Sb683699, T-0047) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34.Figure Siponimod (Baf312) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36.Figure RRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37.Figure SPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38.Figure PPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
39.Figure PRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
40.Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
41.Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
42.Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
43.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
44.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
45.Figure Copaxone (Glatiramer Acetate, Copolymer 1) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
46.Figure Novantrone (Mitoxantrone) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
47.Figure Gilenya (Fingolimod, Fty720) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
48.Figure Aubagio (Teriflunomide) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
49.Figure Tecfidera (Dimethyl Fumarate) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
50.Figure Firategrast (Sb683699, T-0047) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
51.Figure Siponimod (Baf312) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
52.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53.Figure RRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54.Figure SPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55.Figure PPMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56.Figure PRMS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57.Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59.Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60.Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61.Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62.Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63.Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64.Figure Copaxone (Glatiramer Acetate, Copolymer 1) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65.Figure Novantrone (Mitoxantrone) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
66.Figure Gilenya (Fingolimod, Fty720) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
67.Figure Aubagio (Teriflunomide) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
68.Figure Tecfidera (Dimethyl Fumarate) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
69.Figure Firategrast (Sb683699, T-0047) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
70.Figure Siponimod (Baf312) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
71.Figure Others
